Rifampicin, a keystone inducer of drug metabolism: From Herbert Remmer's pioneering ideas to modern concepts

Drug Metabolism Reviews

Volumn 36, Issue 3-4, 2004, Pages 497-509

  Bolt, Hermann M ^a  

^a LEIBNIZ RESEARCH CENTRE FOR WORKING ENVIRONMENT AND HUMAN FACTORS   (Germany)

Author keywords

Clotrimatol; CYP3A4; Drug interactions; Induction; Oral contraceptives; Pregnane X receptors; Pregnenolone 16 carbonitrile; Rifampicin; Rifamycines

Indexed keywords

BARBITURIC ACID DERIVATIVE; CLOTRIMAZOLE; CYTOCHROME P450; CYTOCHROME P450 3A4; DEXAMETHASONE; ESTROGEN HYDROXYLASE; ETHINYLESTRADIOL; GLUCOCORTICOID; GROWTH HORMONE; HYDROCORTISONE; LIOTHYRONINE; METHYLPREDNISOLONE; MIFEPRISTONE; ORAL CONTRACEPTIVE AGENT; OXYGENASE; PHENOBARBITAL; PREGNANE X RECEPTOR; RIFAMPICIN; UNCLASSIFIED DRUG;

DRUG CLEARANCE; DRUG HALF LIFE; DRUG HYDROXYLATION; DRUG MECHANISM; DRUG METABOLISM; ENZYME ASSAY; ENZYME INDUCTION; HUMAN; HYDROCORTISONE RELEASE; LIVER MICROSOME; MOLECULAR CLONING; NONHUMAN; REVIEW; SEQUENCE HOMOLOGY; SPECIES DIFFERENCE; XENOBIOTIC METABOLISM;

EID: 7644233521     PISSN: 03602532     EISSN: None     Source Type: Journal    
DOI: 10.1081/DMR-200033432     Document Type: Review

References (68)

1. Alexanderson, B., Price Evans, D. A., Sjöqvist, F. (1969). Steady-state plasma levels of nortriptyline in twins: influence of genetic factors and drug therapy. Brit. Med. J. 764-768.
2. Altschuler, S. L., Valenteen, J. W. (1974). Amenorrhea following rifampicin administration during oral contraceptive use. Obstet. Gynecol. 44:771-772.
3. Back, D. J., Breckenridge, A. M., Orme, M. L. (1983). Drug interactions with oral contraceptive steroids. IPPF Med. Bull. 17:1-2.
4. Bertilsson, G., Heidrich, J., Svensson, K., Asman, M., Jendeberg, L., Sydowbackman, M., Ohlsson, R., Postlind, H., Blomqvist, P., Berkenstam, A. (1998). Identification of a human nuclear receptor defines a new signalling pathway for CYP3A induction. Proc. Natl. Acad. Sci. U. S. A. 95:12208-12213.
5. Blumberg, B., Kang, K., Bolado, J., Chen, H., Craig A., Moreno, T., Umesono, K., Perlmann, T., DeRobertis, E., Evans, R. (1998). BXR, an embryonic orphan nuclear receptor activated by a novel class of endogenous benzoate metabolites. Genes Dev. 12:1269-1277.
6. Bolt, H. M. (1979). Metabolism of estrogens: natural and synthetic. Pharm. Ther. 4:155-181.
7. Bolt, H. M. (1980). Drug interactions involving oral contraceptives. Rev. Drug Metab. Drug Interact. 3:31-45.
8. Bolt, H. M. (1994). Interactions between clinically used drugs and oral contraceptives. Environ. Health Perspect. 102(Suppl. 9):35-38.
9. Bolt, H. M., Kappus, H. (1973). Effect of clotrimazol treatment on the demethylation of mestranol. Harm. Metab. Res. 5:234.
10. Bolt, H. M., Bolt, W. H. (1974a). Pharmacokinetics of mestranol in relation to its oestrogenic activity. Eur. J. Clin. Pharmacol. 7:295-305.
11. Bolt, H. M., Bolt, M. (1974b). Die Wirkungsinterferenzen zwischen Rifampicin und oralen Kontrazeptiva. Internist 15:571-572.
12. Bolt, H. M., Remmer, H. (1976). Implication of rifampicin-quinone in the irreversible binding of rifampicin to macromolecules. Xenobiotica 6:21-32.
13. Bolt, H. M., Kappus, H., Bolt, M. (1975). Effect of rifampicin treatment on the metabolism of oestradiol and 17-alpha-ethinyl-oestradiol by human liver microsomes. Eur. J. Clin. Pharmacol 8:301-307.
14. Bolt, H. M., Bolt, M., Kappus, H. (1977). Interaction of rifampicin treatment with pharmacokinetics and metabolism of ethinyloestradiol in man. Acta Endocrinol. 85:189-197.
15. Brodie, B. B., Axelrod, J. (1950). The fate of antipyrine in man. J. Pharm. (Baltimore) 98:97-104.
16. Buffington, G. A., Dominguez, J. H., Piering, W. F., Hebert, L. A., Kauffman, M., Lemann, J. (1976). Interaction of rifampicin and glucocorticoids. J. Am. Med. Assoc. 236:1958-1960.
17. Butler, T. C., Mahaffe, C., Wadell, C. W. (1954). Phenobarbital: studies of elimination, accumulation, tolerance, and dosage schedules. J. Pharmacol. Exp. Ther. 111:425-435.
18. Chen, Y., Ferguson, S. S., Negishi, M., Goldstein, J. A. (2004). Induction of human CYP2C9 by rifampicin, hyperforin, and phenobarbital is mediated by the pregnane X receptor. J. Pharmacol. Exp. Ther. 308:495-501.
19. Daujat, M., Pichard, L., Fabre, I., Pineau, T., Fabre, G., Bonfils, C., Maurel, P. (1991). Induction protocols for cytochromes P450IIIA in vivo and in primary cultures of animal and human hepatocytes. Methods Enzymol. 206:345-353.
20. Dussault, I., Yoo, H.-D., Lin, M., Wang, E., Fan, M., Batta, A. K., Salen, G., Erickson, S. K., Forman, B. M. (2003). Identification of an endogenous ligand that activates pregnane X receptor-mediated sterol clearance. Proc. Natl. Acad. Sci. U. S. A. 100:833-838.
21. Edwards, O. M., Courtenay-Evans, R. J., Galley, J. M., Hunter, J., Tait, A. D. (1974). Changes in cortisol metabolism following rifampicin treatment. Lancet 2:549-551.
22. Geick, A., Eichelbaum, M., Burk, O. (2001). Nuclear receptor response elements mediate induction of intestinal MDR1 by rifampicin. J. Biol. Chem. 276:14587-14851.
23. Goodwin, B., Hodgson, E., Liddle, C. (1999). The orphan human pregnan X receptor mediates the transcriptional activation of CYP3A4 by rifampicin through a distal enhancer module. Mol. Pharmacol. 56:1329-1339.
24. Guengerich, F. P. (1990a). Inhibition of oral contraceptive steroid-metabolizing enzymes by steroids and drugs. Am. J. Obstet. Gynecol. 1-3:2159-2163.
25. Guengerich, F. P. (1990b). Mechanism-based inactivation of human liver microsomal cytochrome P-450 III A4 by gestodene. Chem. Res. Toxicol. 3:363-371.
26. Guengerich, F. P. (1990c). Metabolism of 17 alpha-ethynylestradiol in humans. Life Sci. 47:1981-1988.
27. Helton, E. D., Goldzieher, J. W. (1977). Metabolism of ethynyl estrogens. J. Toxicol. Environ. Health 3:231-241.
28. Jones, S. A., Moore, L. B., Shenk, J. L., Wisely, G. B., Hamilton, G. A., McKee, D. D., Tomkinson, N. C. O., LeCluyse, E. L., Lambert, M. H., Willson, T. M., Kliewer, S. A., Moore, J. T. (2000). The pregnane X receptor, a promiscuous nuclear xenobiotic receptor that has diverged during evolution. Mol. Endocrinol. 14:27-39.
29. Kliewer, S. A., Moore, J. T., Wade, L., Staudinger, J. L., Watson, M. A., Jones, S. A., McKee, D. D., Oliver, B. B., Willson, T. M., Zetterstrom, R. H., Perlmann, T., Lehmann, J. M. (1998). An orphan nuclear receptor activated by pregnanes defines a novel steroid signalling pathway. Cell 92:73-82.
30. Kozarek, T. A., Schuetz, E. G., Strom, S. C., Fisher, R. A., Guzelian, P. S. (1995). Comparative analysis of cytochrome P450 3A induction in primary cultures of rat, rabbit, and human hepatocytes. Drug Metab. Dispos. 23:415-421.
31. Kropp, R. (1974). Rifampicin und Ovulationshemmer. Prax. Pneumologie 28:270-272.
32. 14C- ethynylestradiol metabolites in women. Contraception 1:47-55.
33. Lafaix, C., Cadoz, M., Richard, A., Patouillard, P. (1976). Effet "antipilule" de la rifampicine. Med. Hyg. (Genève) 34:181-182.
34. Lay, B., Hildebrandt, A. G., Roots, I. (1976). The specificity of response of in vitro parameters of drug metabolism to different enzyme inducers in the Guinea pig. Naunyn-Schmiedeberg's Arch. Pharmacol. Suppl. 293:R52.
35. LeCluyse, E. L. (2001). Pregnane X receptor: molecular basis for species differences in CYP3A induction by xenobiotics. Chem. Biol. Interact. 134:283-289.
36. Lehmann, J., McKee, D., Watson, M., Willson, T., Moore, J., Kliewer, S. (1998). The human orphan nuclear receptor PXR is activated by compounds that regulate CYP3A4 gene expression and cause drug interactions. J. Clin. Invest. 102:1016-1023.
37. Li, A. P., Kaminski, D. L., Rasmussen, A. (1995). Substrates of human hepatic cytochrome P450 3A4. Toxicology 104:1-8.
38. Liddle, C., Goodwin, B. J., George, J., Tapner, M., Farrell, G. C. (1998). Separate and interactive regulation of cytochrome P450 3A4 by triiodothyronine, dexamethasone, and growth hormone in cultured hepatocytes. J. Clin. Endocrinol. Metab. 83:2411-2416.
39. Mae, T., Hosoe, K., Yamamoto, T., Hidaka, T., Ohashi, T., Kleeman, J. M., Adams, P. E. (1998). Effect of a new rifamycin derivative, rifalazil, on liver microsomal enzyme induction in rat and dog. Xenobiotica 28:759-766.
40. Michot, F., Bürgi, M., Büttner, J. (1970). Rimactan (Rifampicin) und Antikoagulantien-therapie. Schweiz. Med. Wochenschr. 100:583-584.
41. Moore, J. T., Kliewer, S. A. (2000). Use of the nuclear receptor PXR to predict drug interactions. Toxicology 153:1-10.
42. Nocke-Finck, L., Breuer, H., Reimers, D. (1973). Wirkung von Rifampicin auf den Menstruationszyklus und die Östrogenausscheidung bei Einnahme oraler Kontrazeptiva. Dtsch. Med. Wochenschr. 98:1521-1523.
43. Olsen, A. K., Hansen, K. T., Friis, C. (1997). Pig hepatocytes as an in vitro model to study the regulation of human CYP3A4: prediction of drug-drug interactions with 17-alpha-ethynylestradiol. Chem. Biol. Interact. 107:93-108.
44. Otani, G., Remmer, H. (1975). The role of microsomal NADPH-cytochrome reductase in the metabolism of rifampicin. Naunyn-Schmiedeberg's Arch. Pharmacol. Suppl. 287:R76.
45. Pessayre, D., Mazel, P. (1976). Induction and inhibition of hepatic drug metabolizing enzymes by rifampicin. Biochem. Pharmacol. 25:943-945.
46. Peters, U., Hausamen, T. U., Grosse-Brockhoff, F. (1974). Einfluss von Tuberkulostatika auf die Pharmakokinetik des Digitoxins. Dtsch. Med. Wochenschr. 99:2381-2386.
47. Quinn, C. P., Axelrod, J., Brodie, B. B. (1958). Species, strain and sex differences in metabolism of hexobarbitone, amidopyrine, antipyrine, and aniline. Biochem. Pharmacol. 1:152-159.
48. Rae, J. M., Johnson, M. D., Lippman, M. E., Flockhart, D. A. (2001). Rifampicin is a selective, pleiotropic inducer of drug metabolism: studies with cDNA and oligonucleotide expression assays. J. Pharacol. Exp. Ther. 299:849-857.
49. Reimers, D., Jezek, A. (1971). Rifampicin und andere Antituberkulotika bei gleichzeitiger oraler Kontrazeption. Prax. Pneumologie 25:255-262.
50. Remmer, H., Hirschmann, J., Greiner, I. (1969). Die Bedeutung von Kumulation und Elimination für die Dosierung von Phenytoin (Diphenylhydantoin). Dtsch. Med. Wschr. 94:1265-1272.
51. Remmer, H., Schoene, B., Fleischmann, R. A. (1973a). Induction of the unspecific microsomal hydroxylase in the human liver. Drug Metab. Dispos. 1:224-230.
52. Remmer, H., Schoene, B., Fleischmann, R. A., Held, H. (1973b). Induction of the unspecific microsomal hydroxylase in the human liver. In: The Liver. Quantitative Aspects of Structure and Function. Basel: Karger, pp. 232-239.
53. Schoene, B., Fleischmann, R. A., Remmer, H., v. Oldershausen, H. F. (1972). Determination of drug metabolizing enzymes in needle biopsies of human liver. Europ. J. Clin. Pharmacol. 4:65-73.
54. Schuetz, E. G., Schuetz, J. D., Strom, S. C., Thompson, M. T., Fisher, R. A., Molowa, D. T., Li, D., Guzelian, P. S. (1993). Regulation of human liver cytochromes P-450 in family 3A in primary and continuous culture of human hepatocytes. Hepatology 18:1254-1262.
55. Self, T. H., Mann, R. B. (1975). Warfarin and rifampicin interaction. Chest 67:490-491.
56. Skolnick, J. L., Stoler, B. S., Katz, D. B., Anderson, W. H. (1976). Rifampicin, oral contraceptives, and pregnancy. JAMA 236:1382.
57. Snyder, R., Remmer, H. (1979). Classes of hepatic microsomal mixed function oxidase inducers. Pharm. Ther. 7:203-244.
58. Solymoss, B., Werringloer, J., Toth, S. (1971). The influence of pregnenolone-16α-carbonitrile on hepatic mixed-function oxygenases. Steroids 17:427-433.
59. Syvälahti, E. R., Pihlajamäki, K. K., Lisalo, E. J. (1974). Rifampicin and drug metabolism. Lancet 2:232-233.
60. Teng, S., Jekerle, V., Piquette-Miller, M. (2003). Induction of ABCC3 (MRP3) by pregnane X receptor activators. Drug Metab. Dispos. 31:1296-1299.
61. Thier, R., Brüning, T., Roos, P. H., Bolt, H. M. (2002). Cytochrome P450 1B1, a new keystone in gene environment interactions related to human head and neck cancer? Arch. Toxicol. 76:249-256.
62. Vesell, E. S., Page, J. G. (1968). Genetic control of drug levels in man: phenylbutazone. Science 159:1479-1480.
63. Vessell, E. S., Page, J. G., Passananti, G. T. (1971). Genetic and environmental factors affecting ethanol metabolism in man. Clin. Pharm. Ther. 12:192-201.
64. Waxman, D. J., Lapenson, D. P., Aoyama, T., Gelboin, H. V., Gonzalez, F. J., Korzekwa, K. (1991). Steroid hormone hydroxylase specificities of eleven cDNA-expressed human cytochromes P450s. Arch. Biochem. Biophys. 290:160-166.
65. Williams, M. C., Helton, E. D., Goldzieher, J. W. (1975). The urinary metabolites of 17-alpha-ethynylestradiol in women. Steroids 25:229-246.
66. Yamada, S., Iwai, K. (1976). Induction of hepatic cortisol-6-hydroxylase by rifampicin. Lancet 2:366.
67. Zilly, W., Breimer, D. D., Richter, R. (1975). Induction of drug metabolism in man after rifampicin treatment measured by increased hexobarbital and tolbutamide clearance. Eur. J. Clin. Pharmacol. 9:219-227.
68. Zilly, W., Breimer, D. D., Richter, E. (1977). Stimulation of drug metabolism by rifampicin in patients with cirrhosis or cholestasis measured by increased hexobarbital and tolbutamide clearance. Eur. J. Clin. Pharmacol. 11:287-293.